Proxemis & O’Shaughnessy

Revolutionising research The Lord O’Shaughnessy review

In line with the findings of this report, Proxemis can support you to:

We welcomed the thoughtful and insightful independent report published 26 May 2023: Commercial clinical trials in the UK: the Lord O’Shaughnessy review. This review examines commercial clinical trials, their impact, and the challenges they face. The report emphasises the importance of patient-centricity, proposing improved communication with, and involvement of patients in trial design. Streamlining regulatory processes and creating a centralised database for patient-trial matching are recommended to address recruitment challenges. Enhancing transparency and data sharing is also highlighted, with suggestions including a comprehensive database of commercial trials and the publication of all trial results. Calling out the UK’s falling global ranking in the delivery of clinical trials, Lord O’Shaughnessy makes 27 recommendations to safeguard our position as a global leader by not only revitalising our clinical trial activity along traditional lines, but creating an environment where innovation can flourish.

Unlock the potential of primary care

Recruit high-potential candidates at speed and scale

Improve representation through trial participant diversity

Enhance patient access into clinical trials

Embed clinical research into day-to-day healthcare

Deliver financial incentives for primary care

Embrace decentralised and innovative trial approaches

Enable community pharmacies to support clinical trials

Implement research findings into healthcare systems 3

2